114 related articles for article (PubMed ID: 8930202)
1. Methoclocinnamox: agonist and antagonist effects of a novel long-lasting opioid in rhesus monkeys.
Butelman ER; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1996 Nov; 279(2):934-8. PubMed ID: 8930202
[TBL] [Abstract][Full Text] [Related]
2. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
[TBL] [Abstract][Full Text] [Related]
3. In vivo determination of mu opioid receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox.
Zernig G; Butelman ER; Lewis JW; Walker EA; Woods JH
J Pharmacol Exp Ther; 1994 Apr; 269(1):57-65. PubMed ID: 8169852
[TBL] [Abstract][Full Text] [Related]
4. 3-Alkyl ethers of clocinnamox: delayed long-term mu-antagonists with variable mu efficacy.
Husbands SM; Sadd J; Broadbear JH; Woods JH; Martin J; Traynor JR; Aceto MD; Bowman ER; Harris LS; Lewis JW
J Med Chem; 1998 Aug; 41(18):3493-8. PubMed ID: 9719602
[TBL] [Abstract][Full Text] [Related]
5. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
6. Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of mu-selective agonist and antagonist activity.
McLaughlin JP; Hill KP; Jiang Q; Sebastian A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1999 Apr; 289(1):304-11. PubMed ID: 10087018
[TBL] [Abstract][Full Text] [Related]
7. Clocinnamox antagonism of the antinociceptive effects of mu opioids in squirrel monkeys.
Pitts RC; Allen RM; Walker EA; Dykstra LA
J Pharmacol Exp Ther; 1998 Jun; 285(3):1197-206. PubMed ID: 9618423
[TBL] [Abstract][Full Text] [Related]
8. Buprenorphine and methoclocinnamox: agonist and antagonist effects on respiratory function in rhesus monkeys.
Kishioka S; Paronis CA; Lewis JW; Woods JH
Eur J Pharmacol; 2000 Mar; 391(3):289-97. PubMed ID: 10729371
[TBL] [Abstract][Full Text] [Related]
9. Agonist and antagonist effects of dynorphin A-(1-13) in a thermal antinociception assay in rhesus monkeys.
Butelman ER; France CP; Woods JH
J Pharmacol Exp Ther; 1995 Oct; 275(1):374-80. PubMed ID: 7562573
[TBL] [Abstract][Full Text] [Related]
10. Effects of gonadal steroid hormone treatments on opioid antinociception in ovariectomized rhesus monkeys.
Negus SS; Mello NK
Psychopharmacology (Berl); 2002 Jan; 159(3):275-83. PubMed ID: 11862360
[TBL] [Abstract][Full Text] [Related]
11. Opioid antinociception in ovariectomized monkeys: comparison with antinociception in males and effects of estradiol replacement.
Negus SS; Mello NK
J Pharmacol Exp Ther; 1999 Sep; 290(3):1132-40. PubMed ID: 10454487
[TBL] [Abstract][Full Text] [Related]
12. Clocinnamox: a novel, systemically-active, irreversible opioid antagonist.
Comer SD; Burke TF; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1992 Sep; 262(3):1051-6. PubMed ID: 1326622
[TBL] [Abstract][Full Text] [Related]
13. Butorphanol: characterization of agonist and antagonist effects in rhesus monkeys.
Butelman ER; Winger G; Zernig G; Woods JH
J Pharmacol Exp Ther; 1995 Feb; 272(2):845-53. PubMed ID: 7853203
[TBL] [Abstract][Full Text] [Related]
14. Irreversible opioid antagonist effects of clocinnamox on opioid analgesia and mu receptor binding in mice.
Burke TF; Woods JH; Lewis JW; Medzihradsky F
J Pharmacol Exp Ther; 1994 Nov; 271(2):715-21. PubMed ID: 7965787
[TBL] [Abstract][Full Text] [Related]
15. Very long-acting narcotic antagonists: the 14 beta-p-substituted cinnamoylaminomorphinones and their partial mu agonist codeinone relatives.
Aceto MD; Bowman ER; May EL; Harris LS; Woods JH; Smith CB; Medzihradsky F; Jacobson AE
Arzneimittelforschung; 1989 May; 39(5):570-5. PubMed ID: 2547389
[TBL] [Abstract][Full Text] [Related]
16. Use of irreversible antagonists to determine the relative efficacy of mu-opioids in a pigeon drug discrimination procedure: comparison of beta-funaltrexamine and clocinnamox.
Barrett AC; Smith ES; Picker MJ
J Pharmacol Exp Ther; 2003 Jun; 305(3):1061-70. PubMed ID: 12649297
[TBL] [Abstract][Full Text] [Related]
17. Clocinnamox antagonism of opioid suppression of schedule-controlled responding in rhesus monkeys.
Butelman ER; Negus SS; Lewis JW; Woods JH
Psychopharmacology (Berl); 1996 Feb; 123(4):320-4. PubMed ID: 8867870
[TBL] [Abstract][Full Text] [Related]
18. Differentiation of kappa opioid agonist-induced antinociception by naltrexone apparent pA2 analysis in rhesus monkeys.
Ko MC; Butelman ER; Traynor JR; Woods JH
J Pharmacol Exp Ther; 1998 May; 285(2):518-26. PubMed ID: 9580592
[TBL] [Abstract][Full Text] [Related]
19. Antinociceptive and respiratory effects of nalbuphine in rhesus monkeys.
Gerak LR; Butelman ER; Woods JH; France CP
J Pharmacol Exp Ther; 1994 Nov; 271(2):993-9. PubMed ID: 7965822
[TBL] [Abstract][Full Text] [Related]
20. Effects of systemically administered dynorphin A(1-17) in rhesus monkeys.
Butelman ER; Harris TJ; Perez A; Kreek MJ
J Pharmacol Exp Ther; 1999 Aug; 290(2):678-86. PubMed ID: 10411578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
